Seamus Fernandez
Stock Analyst at Guggenheim
(4.77)
# 121
Out of 5,030 analysts
109
Total ratings
63.29%
Success rate
42.86%
Average return
Main Sectors:
Stocks Rated by Seamus Fernandez
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Reiterates: Buy | $948 | $794.61 | +19.30% | 20 | Oct 16, 2025 | |
| CDTX Cidara Therapeutics | Maintains: Buy | $70 → $167 | $100.96 | +65.41% | 5 | Sep 25, 2025 | |
| MBX MBX Biosciences | Maintains: Buy | $44 → $84 | $13.14 | +539.27% | 3 | Sep 23, 2025 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $17 → $25 | $14.74 | +69.61% | 2 | Sep 15, 2025 | |
| TENX Tenax Therapeutics | Maintains: Buy | $15 → $14 | $6.76 | +107.10% | 2 | Aug 14, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $92 → $90 | $27.27 | +230.03% | 2 | Aug 7, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $119 → $120 | $108.99 | +10.10% | 2 | Aug 6, 2025 | |
| APGE Apogee Therapeutics | Reiterates: Buy | $116 | $54.06 | +114.58% | 8 | Jul 2, 2025 | |
| ARQT Arcutis Biotherapeutics | Reiterates: Buy | n/a | $20.62 | - | 3 | Apr 3, 2025 | |
| PCVX Vaxcyte | Reiterates: Buy | $160 | $42.28 | +278.43% | 4 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $56 | $52.77 | +6.12% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $42.66 | - | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $130 → $122 | $83.90 | +45.41% | 14 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $43.99 | - | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.81 | - | 3 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | n/a | $21.00 | - | 2 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $43.36 | - | 12 | Oct 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $53.87 | - | 2 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $131.59 | - | 6 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.17 | - | 1 | Feb 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $56 → $54 | $1.90 | +2,742.11% | 1 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $45 | $26.57 | +69.36% | 3 | Mar 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $36 → $38 | $84.52 | -55.04% | 6 | Feb 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $35 → $38 | $24.32 | +56.25% | 3 | Jan 31, 2018 |
Eli Lilly and Company
Oct 16, 2025
Reiterates: Buy
Price Target: $948
Current: $794.61
Upside: +19.30%
Cidara Therapeutics
Sep 25, 2025
Maintains: Buy
Price Target: $70 → $167
Current: $100.96
Upside: +65.41%
MBX Biosciences
Sep 23, 2025
Maintains: Buy
Price Target: $44 → $84
Current: $13.14
Upside: +539.27%
Amylyx Pharmaceuticals
Sep 15, 2025
Maintains: Buy
Price Target: $17 → $25
Current: $14.74
Upside: +69.61%
Tenax Therapeutics
Aug 14, 2025
Maintains: Buy
Price Target: $15 → $14
Current: $6.76
Upside: +107.10%
Structure Therapeutics
Aug 7, 2025
Maintains: Buy
Price Target: $92 → $90
Current: $27.27
Upside: +230.03%
Rhythm Pharmaceuticals
Aug 6, 2025
Maintains: Buy
Price Target: $119 → $120
Current: $108.99
Upside: +10.10%
Apogee Therapeutics
Jul 2, 2025
Reiterates: Buy
Price Target: $116
Current: $54.06
Upside: +114.58%
Arcutis Biotherapeutics
Apr 3, 2025
Reiterates: Buy
Price Target: n/a
Current: $20.62
Upside: -
Vaxcyte
Mar 12, 2025
Reiterates: Buy
Price Target: $160
Current: $42.28
Upside: +278.43%
Feb 25, 2025
Initiates: Buy
Price Target: $56
Current: $52.77
Upside: +6.12%
Feb 24, 2025
Reiterates: Buy
Price Target: n/a
Current: $42.66
Upside: -
Jan 17, 2025
Maintains: Buy
Price Target: $130 → $122
Current: $83.90
Upside: +45.41%
Oct 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $43.99
Upside: -
Apr 29, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.81
Upside: -
Jul 14, 2023
Maintains: Buy
Price Target: n/a
Current: $21.00
Upside: -
Oct 10, 2022
Downgrades: Neutral
Price Target: n/a
Current: $43.36
Upside: -
May 31, 2022
Upgrades: Buy
Price Target: n/a
Current: $53.87
Upside: -
Feb 25, 2020
Downgrades: Neutral
Price Target: n/a
Current: $131.59
Upside: -
Feb 3, 2020
Downgrades: Neutral
Price Target: n/a
Current: $7.17
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $56 → $54
Current: $1.90
Upside: +2,742.11%
Mar 8, 2018
Maintains: Market Perform
Price Target: $60 → $45
Current: $26.57
Upside: +69.36%
Feb 6, 2018
Maintains: Market Perform
Price Target: $36 → $38
Current: $84.52
Upside: -55.04%
Jan 31, 2018
Maintains: Market Perform
Price Target: $35 → $38
Current: $24.32
Upside: +56.25%